<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130533</url>
  </required_header>
  <id_info>
    <org_study_id>CIBOMA 2004-01</org_study_id>
    <secondary_id>2005-002838-36</secondary_id>
    <nct_id>NCT00130533</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients</brief_title>
  <official_title>Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Capecitabine Following Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IBEROAMERICAN COALITION FOR BREAST ONCOLOGY RESEARCH (CIBOMA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine
      after standard chemotherapy for patients with early triple negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be stratified as per investigational site, previous adjuvant chemotherapy
      (anthracyclines versus anthracyclines plus taxanes), and number of affected axillary lymph
      nodes (0, 1-3, &gt;= 4). Node negative patients must present a tumour size &gt; 2 cm to be
      eligible. At least 6 lymph nodes must be analysed to confirm the number of affected nodes.
      Patients will be randomised to receive: 8 courses of capecitabine 1000 mg/m2 by mouth, twice
      a day (p.o. bid) for 14 days, followed by a 7 day rest versus observation.

      Tissue samples must be analysed by a central laboratory, to confirm estrogen receptor (ER),
      progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2), cytokeratins
      (CK) 5/6 and epidermal growth factor receptor (EGFR) status.

      The following data were obtained from the database of the &quot;El Alamo&quot; project. One thousand
      six hundred and twenty-seven (1,627) in total were considered during the years 1990 to 1997.
      The population is formed of patients with operable breast cancer, with surgery, positive
      nodes, and negative hormone receptors, or negative nodes, negative hormone receptors and T2-3
      tumors.

      For these patient groups, estimated 5-year disease-free survival is 64.72%. Assuming an
      exponential distribution, the aim is to detect an increase of 64.72% to 73.7% in 5 years
      Disease Free survival rate corresponds to a Hazard Ratio of 0.701 and a risk reduction of
      about 30%, with a power of 80% using a two-tailed log-rank test at 0.05 and whereas 4 years
      of recruitment period and 3 years of follow-up period. We would need 255 events, 834 patients
      without considering any dropouts.

      Considering a drop-out rate of 5% post-randomization, the final sample size will be 876
      patients, 438 per treatment arm.

      The sample size calculation was performed by the program package &quot;EAST&quot; version 5.2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Actual">February 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS) Events</measure>
    <time_frame>5 years</time_frame>
    <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) Events by Phenotype</measure>
    <time_frame>5 years</time_frame>
    <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Event</measure>
    <time_frame>5 years</time_frame>
    <description>OS event is defined as the death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Experienced Adverse Events (AE)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety will be assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">876</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Xeloda (capecitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mgrs/m2 twice a day, tablets, 8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Xeloda (capecitabine)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3).
             Tumours must be HER2 negative. Time window between end of adjuvant chemotherapy and
             study randomization must be less than 8 weeks. In patients receiving adjuvant
             radiotherapy, time window allowed between last session and randomisation is 4 weeks.

          -  Surgery must consist of mastectomy or conservative surgery with axillary lymph node
             dissection. Margins free of disease and ductal carcinoma in-situ (DCIS) are required.
             Lobular carcinoma is not considered a positive margin.

          -  Node negative patients with tumour size &gt; 2 cm.

          -  Positive axillary lymph nodes defined as at least 1 out of 6 nodes with presence of
             disease. If sentinel node technique is used, sentinel node can be the only node
             affected. Patients belonging to the following classifications are eligible: pN1a
             (Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2.0 mm),
             pN2a (Metastases in 4-9 axillary lymph nodes (at least one tumor deposit greater than
             2 mm)), pN3a (Metastases in 10 or more axillary lymph nodes [at least one tumor
             deposit greater than 2 mm]; or metastases to the infraclavicular [level III axillary
             lymph] nodes).

          -  Status of hormone receptors in primary tumour. Negative results must be available
             before the end of adjuvant chemotherapy.

          -  Patients must not present evidence of metastatic disease.

          -  Negative status of HER2 in primary tumour, known before randomization.

          -  Adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines and/or
             taxanes.

          -  Age &gt;= 18 and &lt;= 70 years old.

          -  Performance status (Karnofsky index) &gt;= 80.

          -  Laboratory results (within 14 days prior to randomization):

          -  Hematology:

               -  neutrophils &gt;= 1.5 x 10e9/l;

               -  platelets &gt;= 100x 10e9/l;

               -  hemoglobin &gt;= 10 mg/dl

          -  Hepatic function:

               -  total bilirubin &lt;= 1 upper normal limit (UNL);

               -  Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or
                  SGPT) &lt;= 2.5 UNL;

               -  alkaline phosphatase &lt;= 2.5 UNL.

               -  If values of SGOT and SGPT &gt; 1.5 UNL are associated to alkaline phosphatase &gt; 2.5
                  UNL, patient is not eligible.

          -  Renal Function:

               -  creatinine &lt;= 175 Âµmol/l (2 mg/dl).

               -  creatinine clearance &gt;= 60 ml/min.

          -  Pharmacogenetics:

               -  one blood sample is needed for single nucleotide polymorphism (SNP) assessment.

          -  Patients able to comply with treatment and study follow-up.

          -  Negative pregnancy test done in the 14 previous days to randomization.

        Exclusion Criteria:

          -  Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any
             malignancy.

          -  Pregnant or lactating women. Adequate contraceptive methods must be used during
             chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14
             previous days to randomization.

          -  Bilateral invasive breast cancer.

          -  Any T4 or M1 tumour.

          -  Axillary lymph nodes: patients belonging to the following classifications are
             excluded: pN1b (Metastases in internal mammary nodes with micrometastases or
             macrometastases detected by sentinel lymph node biopsy but not clinically detected),
             pN1c (Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes with
             micrometastases or macrometastases detected by sentinel lymph node biopsy but not
             clinically detected), pN2b (Metastases in clinically detected internal mammary lymph
             nodes in the absence of axillary lymph node metastases), pN3b (Metastases in
             clinically detected ipsilateral internal mammary lymph nodes in the presence of one or
             more positive axillary lymph nodes; or in more than three axillary lymph nodes and in
             internal mammary lymph nodes with micrometastases or macrometastases detected by
             sentinel lymph node biopsy but not clinically detected), pN3c (Metastases in
             ipsilateral supraclavicular lymph nodes).

          -  Any other serious medical pathology, such as congestive heart failure, unstable
             angina, history of myocardial infarction during the previous year, uncontrolled
             hypertension or high risk arrhythmias.

          -  History of neurological or psychiatric disorders, which could preclude the patients to
             free informed consent.

          -  Active uncontrolled infection.

          -  Active peptic ulcer, unstable diabetes mellitus.

          -  Previous or current history of neoplasms different to breast cancer, except for skin
             carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;
             lobular in situ carcinoma.

          -  History of hypersensitivity to capecitabine, fluorouracil.

          -  Patients lacking physical integrity of upper gastrointestinal tract or with history of
             bad absorption syndrome.

          -  History of dihydropyrimidine dehydrogenase (DPD) deficiency.

          -  Anticoagulant treatment with coumadin anticoagulants.

          -  Current treatment with sorivudine or its chemical family.

          -  Concomitant treatment with other investigational products. Participation in other
             clinical trials with a non-marketed drug in the 30 previous days before randomization.

          -  Concomitant treatment with other therapy for cancer.

          -  Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital ClÃ­nico Universitario de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto CatalÃ¡n de OncologÃ­a de L'Hospitalet</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CorporaciÃ³ Sanitaria Parc TaulÃ­</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del EspÃ­ritu Santo</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario MarquÃ©s de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de CastellÃ³n</name>
      <address>
        <city>CastellÃ³n De La Plana</city>
        <state>CastellÃ³n</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>CÃ¡diz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>Donostia-San SebastiÃ¡n</city>
        <state>GuipÃºzcoa</state>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>Donostia-San SebastiÃ¡n</city>
        <state>GuipÃºzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Las Palmas de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario FundaciÃ³n AlcorcÃ³n</name>
      <address>
        <city>AlcorcÃ³n</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoaliciÃ³n Iberoamericana de InvestigaciÃ³n en OncologÃ­a Mamaria (CIBOMA)</name>
      <address>
        <city>San SebastiÃ¡n de los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A CoruÃ±a</name>
      <address>
        <city>A CoruÃ±a</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro OncolÃ³gico de Galicia</name>
      <address>
        <city>A CoruÃ±a</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General YagÃ¼e</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>CÃ¡diz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina SofÃ­a</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de JaÃ©n</name>
      <address>
        <city>JaÃ©n</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Madrid Norte Sanchinarro (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Madrid</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra SeÃ±ora de Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del RocÃ­o</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de OncologÃ­a</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Zamora &quot;RodrÃ­guez Chamorro&quot;</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Zaragoza &quot;Lozano Blesa&quot;</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ciboma.org/</url>
    <description>Sponsor's web</description>
  </link>
  <link>
    <url>http://www.geicam.org/</url>
    <description>Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>July 25, 2019</results_first_submitted>
  <results_first_submitted_qc>October 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple-Negative Early Breast Cancer</keyword>
  <keyword>Maintenance Adjuvant Chemotherapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Basal-like genotype</keyword>
  <keyword>Triple-Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 16, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT00130533/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT00130533/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 2006 and September 2011, 876 patients were recruited, across 80 institutions in 8 countries (Spain, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Venezuela)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Xeloda (Capecitabine)</title>
          <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
        </group>
        <group group_id="P2">
          <title>Observation</title>
          <description>Observation. No intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease relapse</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Interruption of treatment &gt; 3 weeks</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SponsorÂ´s decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second Primary Malignancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xeloda (Capecitabine)</title>
          <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
        </group>
        <group group_id="B2">
          <title>Observation</title>
          <description>Observation. No intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="448"/>
            <count group_id="B2" value="428"/>
            <count group_id="B3" value="876"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="20" upper_limit="79"/>
                    <measurement group_id="B2" value="49" lower_limit="23" upper_limit="82"/>
                    <measurement group_id="B3" value="49" lower_limit="20" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="428"/>
                    <measurement group_id="B3" value="876"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="313"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecuador</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Index Performance Status</title>
          <description>Karnofsky Scale allows patients to be classified as to their functional impairment. The lower the Karnofsky score, the worse the survival for most serious illnesses 100: Normal, no complaints 90: Minor signs or disease symptoms 80: Normal activity with effort 70: Care for self. Unable to carry on normal activity 60: Requires occasional assistance 50: Requires considerable assistance and frequent medical care 40: Disabled. Requires special care and assistance 30: Severly disabled 20: Very sick. Active supportive treatment necessary 10: Moribund 0: Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status at diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Invasive ductal carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="764"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive lobular carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic grade</title>
          <description>Cancer cells are given a Grade (G) when they are removed from the breast and checked under a microscope. The G is based on how much the cancer cells look like normal cells.
G1 or well differentiated (score 3, 4, or 5): cells are slower-growing, and look more like normal breast tissue.
G2 or moderately differentiated (score 6, 7): cells are growing at a speed of and look like cells somewhere between G1 and 3.
G3 or poorly differentiated (score 8, 9): cells look very different from normal and will probably grow and spread faster.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="622"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phenotype by immunohistochemistry (IHC)</title>
          <description>Basal phenotype: Basal-like tumors receive this name because their genetic expression profile is similar to that of a normal basal epithelial cell. These similarities include the absence of expression of the estrogen receptor and other genes related with this and the human epidermal growth factor receptor 2 (HER2) receptor. They also share with the basal epithelial cells overexpression of cytokeratins 5/6 and 17, epidermal growth factor receptor (EGFR) and genes associated with proliferation. p53 mutations in thyrosine are also basal cell characteristics.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Basal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="628"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-basal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at diagnosis</title>
          <description>According to American Joint Committee on Cancer (AJCC) 2002:
Stage (S) I: tumour &lt;2 centimetres (cm)
S II:
S IIA: cancer spread to movable ipsilateral axillary (MIA) Lymph Nodes (LN). tumor &lt;2 cm and spread to MIA LN tumor &gt;2 cm but &gt;5 cm
S IIB:
tumor &gt;2 cm but &lt;5 cm and spread to MIA LN tumor &gt;5 cm
- S III: S IIIA: cancer spread to ipsilateral axillary LN fixed or matted S IIIB: tumor spread to the chest wall or caused swelling or ulceration of the breast or is diagnosed as inflammatory breast cancer.
S IIIC: metastases in ipsilateral infraclavicular LN.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodal status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="486"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1â3 positive nodes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>â¥4 positive nodes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of prior Chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adjuvant (only)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="705"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neoadjuvant (+/- adjuvant)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chemotherapy regimens</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Anthracyclines-based</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Anthracyclines and taxanes-based</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breast surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Conservative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="479"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mastectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary surgery</title>
          <description>axillary lymph node dissection (ALND) sentinel lymph node biopsy (SLNB)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>sentinel lymph node biopsy (SLNB)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>axillary lymph node dissection +/- SLNB</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Radiation therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="698"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS) Events</title>
        <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeloda (Capecitabine)</title>
            <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation. No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Events</title>
          <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival (DFS) Events by Phenotype</title>
        <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeloda (Capecitabine)</title>
            <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation. No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Events by Phenotype</title>
          <description>DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Basal Phenotype</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non basal Phenotype</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Event</title>
        <description>OS event is defined as the death from any cause.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xeloda (Capecitabine)</title>
            <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation. No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Event</title>
          <description>OS event is defined as the death from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
        <description>Safety will be assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events).</description>
        <time_frame>5 years</time_frame>
        <population>The analysis of toxicity was made in all study patients who had received at least 1 treatment cycle, or who had completed the observation period equivalent to 1 cycle.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeloda (Capecitabine)</title>
            <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Observation. No intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
          <description>Safety will be assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events).</description>
          <population>The analysis of toxicity was made in all study patients who had received at least 1 treatment cycle, or who had completed the observation period equivalent to 1 cycle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="436"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xeloda (Capecitabine)</title>
          <description>1000 mgrs/m2 twice a day, tablets, 8 cycles
Capecitabine</description>
        </group>
        <group group_id="E2">
          <title>Observation</title>
          <description>Observation. No intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v. 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="448"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia G 3; Leucopenia G2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperbilirrubinemia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmia NOS</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Infarction and cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ischemia cardiac/Infarction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Coronary vasospam</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis and renal insuficience</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Mucositis Oral cavity and Pharynx</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diarrhea grade 2, Vomiting grade 2, Septic shock grade 5</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ulcer gastric</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of depressive syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia, Diarrhea, Hand foot skin reaction, Acute renal failure</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC ( Urinary)</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC pulmonary/upper respiratory - lung (pneumonia)</sub_title>
                <description>Grade 5</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thorax and left arm pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Showed lumbar column fracture(L4)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <description>Grade 5</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Positive pregnant test performed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Right renal colic</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Thoracic pain grade 2, disnea G-1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Axillary nodular resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism: venous thrombosis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE v. 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="416" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>BILIRUBIN</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>URIC ACID, SERUM-HIGH</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>URIC ACID, SERUM-HIGH</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>IRREGULAR MENSES</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>IRREGULAR MENSES</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>IRREGULAR MENSES</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH: HAND-FOOT SKIN REACTION</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>RASH: HAND-FOOT SKIN REACTION</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>RASH: HAND-FOOT SKIN REACTION</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="436"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

